ISPOR - HTA17 Cost-Effectiveness Analysis of Tocilizumab for The Treatment of COVID-19 in Hospitalised Patients on Corticosteroids, From the Italian NHS Perspective

HTA17 Cost-Effectiveness Analysis of Tocilizumab for The Treatment of COVID-19 in Hospitalised Patients on Corticosteroids, From the Italian NHS Perspective

Abstract

Authors

N Jovanoski A Dario

Full Text Cite This Article

Back to Volume 25, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now